Cure GM1 provided seed funding for, and families from the GM1 community provided dried blood spot samples to the Gelb Laboratory at University of Washington in 2019. This has resulted in a third publication from Gelb that includes GM1 titled: Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis.
